As recent US drug-pricing policy proposals prompt pharmaceutical companies to disclose European price benchmarks, questions are emerging around how these measures may influence market strategy.

According to partner Emmanuelle Trombe in an interview with Le Figaro, some companies may reconsider whether to launch new innovations in Europe as a result.

Click here to access the full article (in French) via paywall.